Have you talked to your doctor about accidental bowel leakage (ABL)? Over 8% of U.S. adults experience accidental bowel leakage (ABL), also known as fecal incontinence. We are recruiting men and women who have ABL to participate in a National Institute of Health (NIH) funded research study investigating the effectiveness, safety, and cost of three FDA approved treatments. There are treatment options that can help
To assess hepatitis C virus treatment and hepatocellular carcinoma surveillance within practices and gauge the feasibility of a program to implement point-of-care risk stratification tools and screening referral systems.
To generate real world evidence on SOC (surgical interventions) for treating complex fistulizing conditions and related outcomes (clinical and patient reported) among patients with the following conditions: CPF-CD, CD- RVF, and CCF.
To estimate the efficacy of BMS-986165 at Week 12
To learn if a new investigational drug (CC-93538) is a safe and effective treatment method for reducing symptoms of Eosinophilic Esophagitis (EoE).
The main goal of this study is to learn how well the study drug works and how safe the study drug is compared with placebo. A placebo is an inactive material that looks like the study drug but does not have any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
The primary objective for this registry is to prospectively study the natural history of IBD, the prevalence and incidence of comorbidities, and targeted adverse events, as well as the utilization patterns and the comparative effectiveness and comparative safety of approved IBD treatments.
This project will define findings of patients referred for colonoscopy following a positive Cologuard® test using retrospective analysis of one community Gastroenterology practice.
To evaluate the efficacy of 2 mg/kg and 4 mg/kg LBM of belapectin compared to placebo in preventing the development of esophageal varices
To create a multi-centered prospective registry of individuals ≥60 years ("older adults") with IBD to quantify prevalence, incidence and progression of frailty, multi-morbidity, physical and cognitive impairment